Same patented chemistry. Two form factors.
Pouch-format test containing scoop, water vessel, and test strip. Visual result reading. Designed for high-volume community distribution through SSPs, CBOs, and harm reduction outreach programs.
Self-contained mechanical device that automates dissolution, strip exposure, and timing. Eliminates user handling variables for higher consistency in clinical settings.
Detailed specifications
Both SC-1 and SC-X share identical detection chemistry and sensitivity. The difference is human error — SC-X mechanically controls the variables that users get wrong with manual testing.
For the most reliable results, SC-X eliminates user error entirely. SC-1 is the right choice when budget is the primary constraint and you need to maximize distribution volume.
Many jurisdictions deploy SC-X at clinical and supervised sites, with SC-1 extending reach through high-volume community distribution where budget is tight. We support hybrid procurement across a single contract.
What this test does not detect
Both SC-1 and SC-X detect fentanyl and 100+ fentanyl analogs, including nitazenes. They do not detect every substance in the drug supply. A negative fentanyl result does not mean a substance is safe.
Xylazine (alone)
Our test detects fentanyl in xylazine-adulterated samples, but does not detect xylazine itself. Pair with dedicated xylazine test strips for full coverage.
Designer benzodiazepines
Bromazolam and other novel benzodiazepines require separate benzodiazepine-specific test strips.
Medetomidine
A veterinary sedative increasingly found in the fentanyl supply (37% co-occurrence in some regions). Not detectable by any fentanyl immunoassay. Dedicated test strips are emerging.
Orphines
A new class of synthetic opioids (benzimidazol-2-ones) that are structurally distinct from both fentanyl and nitazenes. No rapid test currently exists for this class.
No single test strip detects everything in today's drug supply. A comprehensive drug checking approach pairs fentanyl detection with supplementary testing for emerging threats.
Our quarterly drug supply intelligence briefs track which substances are circulating in your region, so your program can prioritize the right supplementary tests.
A fentanyl-positive result should always trigger safer use practices regardless of what else may be present. A fentanyl-negative result should not be interpreted as an all-clear.